Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial. (Q40809928)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

Helicobacter pylori

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Wen-Feng Hsu

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Ming-Jong Bair

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Chieh-Chang Chen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Yi-Chia Lee

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Mei-Jyh Chen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Chien-Chuan Chen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Cheng-Hao Tseng

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Yu-Jen Fang

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Ji-Yuh Lee

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Tsung-Hua Yang

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Jiing-Chyuan Luo

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Jeng-Yih Wu

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Wen-Hsiung Chang

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Chun-Chao Chang

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Chi-Yi Chen

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Po-Yueh Chen

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Chia-Tung Shun

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Hsu-Wei Hung

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Jaw-Town Lin

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Chi-Yang Chang

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Ming-Shiang Wu

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Taiwan Gastrointestinal Disease and Helicobacter Consortium

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

language of work or name

English

0 references

publication date

2 February 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

The American Journal of Gastroenterology

6 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

381-387

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials

6 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

Levofloxacin based sequential and triple therapy compared with standard plus probiotic combination for Helicobacter pylori eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

Evidence-based recommendations for successful Helicobacter pylori treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

Helicobacter pylori eradication therapy research: Ethical issues and description of results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

Sequential Therapy versus Standard Triple-Drug Therapy for Helicobacter pylori Eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.439

Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China

21 January 2018

1 reference

12 December 2020

Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.

1 reference

12 December 2020

Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial.

1 reference

12 December 2020

Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial

1 reference

12 December 2020

A report card to grade Helicobacter pylori therapy

1 reference

12 December 2020

Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection

1 reference

12 December 2020

Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial

1 reference

12 December 2020

Identifiers

DOI

10.1038/AJG.2015.439

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26832653%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference